Bubendorf/Basel, Switzerland and Ibaraki, Japan, September 7th, 2015 – Bachem (SIX: BANB) and ILS announce today that they will strengthen their co-marketing efforts in Japan. The two companies have been establishing a close collaboration for more than a decade, already. Based on a Sales and Marketing agreement which was signed in 2012, ILS is providing Bachem manufactured Active Pharmaceutical Ingredients (API) to Japanese customers. In the course of the acquisition of American Peptide Company, Inc. (APC), based in California USA, and its transfer from ILS to Bachem, both companies underlined their intentions to extend the current business relations. Under the agreement reached, ILS will be the Exclusive Agent for Japan for all peptide-based products of the Bachem Group; this applies to non-GMP research chemicals as well as for cGMP grade API. In addition, ILS will register Drug Master Files in Japan for API manufactured by Bachem.